Companies working on Swine Flu Vaccines
|
You might think that inter-species diseases are a thing of the movies, but in reality viruses, bacteria, and fungus jump between the species they attack. The recent H1N1 pig flu virus had genes from bird flu, and when it migrated to humans, it acquired human genes. Vaccines try to prevent inter-species viruses and include immunity against variations of H1N1, H3N2, H1N2. Viral mutations are not fiction, and vaccination and potent anti-virals are some of our weapons. |
Kleiner Perkins Caufield & Byers
Venture Capital firm with shares in two public companies: BioCryst Pharmaceuticals, and Novavax Roche Holding AG Owner of Tamifly which might be effective against the swine flu virus Glaxo Smith Kline Maker of Relenza which might also be effective agains the pig flu virus Biocryst Pharmaceuticals Maker of key enzymes that block the action of influenza viruses Novavax Viral vaccine maker
Tags: Vaccine Companies
|
Biotechnology advances have allowed us to understand viruses, bacteria, and other pathogens better than ever before. We use genetic engineering, DNA sequencing, microarrays, PCR, and other genomic and proteomic tools to understand pathogens better. We've also developed vaccines and potent antivirals and antibiotics that fight diseases. A proof of this is how much longer life expectancy is Today than it was before the 1940's when antibiotics were invented. |
Comment on "Companies working on Swine Flu Vaccines"
- CDC Audio Rounds: Continue to Vaccinate Patients and Staff Against the Flu (podcast)
- Have You Heard, February 10, 2012: CDC Says U.S. Seeing Latest Flu Season in Nearly Three Decades
- CDC Expert Commentary on Medscape: Variant H3N2 Influenza Virus: What You Should Know with Michael Jhung, MD, MPH
- International Program Highlight: Visits Highlight the Importance of CDC’s Influenza Activities in India
- Have You Heard, February 7, 2012: CDC Recommendations for Influenza Antiviral Medications Remain Unchanged
